Advanced Precision Therapies
Most Cancers are Solid Tumors
Solid Tumor Cancers represent a significant clinical unmet need where current therapies have provided limited relief.
New adoptive cell therapies show promise, however, tumor resistance and relapse are still common.
Cancer vaccines have also shown exciting pre-clinical results but choosing the right vaccine target remains a huge challenge.
Black Canyon Bio’s technology provides a personalized medicine approach to treat solid tumor cancers.
About Us
Black Canyon Bio is a privately held company developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAP) Technology platform. SNAP Technology has product development applications across many cancers and other diseases.
SNAP Technology was developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network, where Dr. Sharma is a Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery, and directs the City of Hope Center for Cancer Prevention and Early Detection.
Team
Our Team has decades of proven experience and leadership in biopharma; supported by a network of expert advisors.
Proprietary Specific Neo-Antigen Peptides (SNAP) Technology Platform
Developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network, where Dr. Sharma is a Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery, and directs the City of Hope Center for Cancer Prevention and Early Detection
Our SNAP Technology Platform is a Major Step Forward for Targeted Therapy
Our technology can be applied to both cancer vaccines and cellular therapies. The process involves several key steps:
- Obtaining tumor cells from the patient.
- Performing genomic analysis of the tumor sample and normal DNA/RNA from the patient to detect patient-specific tumor mutations.
- Computational tools and machine learning algorithms are used through and in-silico assay to predict which of these mutations are likely to form neo-antigens.
- The predicted neo-antigens are then credentialed through a proprietary in-vitro assay, obtaining a set of validated biologically-active neo-antigens.
- Using these neo-antigens we manufacture either an Adoptive Cell Therapy (Tumor Infiltrating Lymphocytes) or a Cancer Vaccine (peptide and mRNA).
Pipeline
